Alterity Therapeutics Limited PRNAF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -76.68% | -76.72% | 75.84% | 70.46% | 75.89% |
| Total Revenue | -76.68% | -76.72% | 75.84% | 70.46% | 75.89% |
| Cost of Revenue | 183.90% | 183.08% | 56.52% | 51.64% | -47.03% |
| Gross Profit | -81.11% | -81.14% | 76.64% | 71.22% | 83.08% |
| SG&A Expenses | 176.28% | 175.83% | 55.66% | 50.91% | -21.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 234.69% | 234.38% | 241.30% | 231.22% | 1,860.00% |
| Total Operating Expenses | 56.40% | 56.15% | 45.86% | 41.41% | -29.51% |
| Operating Income | -128.05% | -127.68% | -39.49% | -35.22% | 46.70% |
| Income Before Tax | -210.21% | -209.70% | -34.15% | -30.06% | 62.06% |
| Income Tax Expenses | -15.60% | -15.49% | -- | -- | 43.42% |
| Earnings from Continuing Operations | -207.12% | -206.61% | -35.02% | -30.89% | 61.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -207.12% | -206.61% | -35.02% | -30.89% | 61.67% |
| EBIT | -128.05% | -127.68% | -39.49% | -35.22% | 46.70% |
| EBITDA | -128.40% | -128.03% | -39.77% | -35.50% | 46.72% |
| EPS Basic | -110.28% | -111.54% | 29.55% | 31.42% | 75.35% |
| Normalized Basic EPS | -47.37% | -47.31% | 29.93% | 31.91% | 64.81% |
| EPS Diluted | -117.76% | -118.27% | 32.02% | 34.04% | 75.35% |
| Normalized Diluted EPS | -47.37% | -47.31% | 29.93% | 31.91% | 64.81% |
| Average Basic Shares Outstanding | 45.31% | 45.31% | 91.58% | 91.58% | 56.02% |
| Average Diluted Shares Outstanding | 45.31% | 45.31% | 91.58% | 91.58% | 56.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |